Its profit after tax (PAT) margin increased sequentially by 195 bps to 5.7%, while its EBITDA margin increased sequentially by 97 bps to 21.1%.
The price band for the IPO has been fixed at Rs 285 to Rs 300 per equity share.
Recommendation: Buy; Target price: Rs 1750
Although it climbed by almost 7% YoY to Rs 9,182.31 crore, the total revenue from operations fell short of the expected Rs 9,358 crore.
Consumer prices increased 0.8% in the June quarter, below expectations of 1.0% and the lowest increase since the third quarter of 2021, according to Australian data.
Recommendation: Buy; Target price: Rs 1650
The product is bioequivalent and therapeutically equivalent to the reference-listed medicine, Mozobil Injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation.
The L&T board also gave the green light for a Rs 10,000 crore share buyback program
Analysts of IIFL Capital Services see COFO continuing on this trajectory by delivering 15%/25% USD revenue/EPS Cagr over FY23-25, driven by execution of strong deal wins and improving margins.
The reorganization will allow the company to capitalize on shared AFS.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
